Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Blood-Cleaning machine could help liver failure patients avoid transplant

NCT ID NCT07329036

Disease control Sponsor: Institute for Clinical and Experimental Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a combined blood-filtering system (DPMAS and plasma exchange) in 25 adults with acute-on-chronic liver failure who are either waiting for a liver transplant or not eligible for one. The goal is to see if this artificial liver support can keep patients alive without a transplant for at least 21 days. The treatment aims to remove toxins from the blood and support vital organ function.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Double Plasma Molecular Adsorption System (DPMAS) combined with Therapeutic Plasma Exchange (TPE)
What this could lead to
If it works, this could provide a temporary liver support option for patients with acute liver failure, potentially reducing the need for urgent liver transplants.
What could go wrong
This is a small early study with only 25 participants, so results may not apply broadly. The treatment is supportive, not a cure, and risks include bleeding or infection from the blood-filtering procedure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 25 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patient, age ≥18 years * Expressed consent to the inclusion * Patient hospitalized on ICU with ALF or ACLF diagnosis * Recently meeting the inclusion to liver transplantation * Present on a waiting list to liver transplant * Unsuitable for inclusion to liver transplantation - indicated for support therapy only, but not indented to palliative care Exclusion Criteria: * Disagreement with the study * Infaust prognosis with expected survival less than 24 hours * Physiologically/biologically very advanced stage patients condition, severe lung disease (Gold criteria 3 or 4), heart failure (functional class NYHA III or IV) or neurological disease, as well as ACLF-3. * Advanced oncological disease (expected life expectancy below 6 months) * Severe degree of Frailty syndrome in secondary severe sarcopenia (muscle and malnutrition) or reduced performance state according

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute liver failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute liver failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute liver failure

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Institute for Clinical and Experimental Medicine (IKEM)

    RECRUITING

    Prague, 14200, Czechia

More trials for these conditions

Other studies related to the condition(s) this trial covers.